Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KSI 301

Drug Profile

KSI 301

Alternative Names: KSI-301

Latest Information Update: 25 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oligasis
  • Developer Kodiak Sciences
  • Class Drug conjugates; Eye disorder therapies; Immunoconjugates
  • Mechanism of Action Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Wet age-related macular degeneration
  • Phase I Diabetic macular oedema; Retinal vein occlusion

Most Recent Events

  • 02 Dec 2019 Kodiak Sciences plans pivotal trials for Retinal vein occlusion, Diabetic macular oedema and Diabetic retinopathy in 2020
  • 12 Nov 2019 Kodiak Sciences announces intention to submit BLA for Retinal vein occlusio and sBLA for wet age-related macular degeneration, diabetic macular oedema to the US FDA in 2022
  • 12 Nov 2019 Kodiak Sciences completes an End of phase II meeting with the US FDA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top